See original here:
MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast...

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh